DIAPH2-AS1 and aplastic anemia: In summary, our results indicate that Epag is a clinically relevant DNA dioxygenase inhibitor and this activity may contribute, in addition to its TPOR agonistic effect, to its efficacy in aplastic anemia, including reexpansion of HSPCs.